Labcorp Holdings Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LH research report →
Range $355 – $420
Price Chart
About the company
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
- CEO
- Adam H. Schechter
- IPO
- 1990
- Employees
- 71,000
- HQ
- Burlington, NC, US
Get TickerSpark's AI analysis on LH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $29.81B
- P/E
- 29.92
- Fwd P/E
- 19.84
- PEG
- 1.53
- P/S
- 2.04
- P/B
- 3.37
- EV/EBITDA
- 16.84
- Div Yield
- 0.78%
- Gross Margin
- 28.96%
- Op Margin
- 10.29%
- Net Margin
- 6.88%
- ROE
- 11.54%
- ROIC
- 7.30%
Latest fiscal year · YoY change
- Revenue
- $13.95B+7.2%
- Gross Profit
- $4.01B+10.7%
- Op Income
- $1.38B
- Net Income
- $876.50M+17.5%
- EPS
- $10.54+18.6%
- OCF Growth
- +3.4%
- FCF Growth
- +10.0%
- 52W High
- $375.10
- 52W Low
- $245.00
- 50D MA
- $333.65
- 200D MA
- $294.36
- Beta
- 0.84
- RSI (14)
- 62
- Avg Volume
- 742.91K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
LabCorp posted a strong Q3 with 7% revenue growth, margin expansion, and 14.5% EPS growth, while raising full-year 2026 guidance and flagging PAMA as a 2027 headwind.· October 28, 2026
- Revenue grew 7% to $3.8 billion, adjusted EPS rose 14.5% to $4.78, and free cash flow was $412 million.
- Adjusted operating margin expanded 60 basis points to 15%, with enterprise margin progression continuing for a sixth straight quarter.
- Diagnostics revenue increased 6.5% to $2.9 billion; BLS revenue rose 8.5% to $867 million, supported by strong central lab demand.
- Management raised full-year 2026 guidance and said the midpoint of enterprise revenue and adjusted EPS was lifted by $65 million and $0.18, respectively.
- LabCorp said the proposed PAMA fee schedule could reduce 2027 reimbursement by about $125 million, but reaffirmed its 2026-2029 long-term outlook.
- The company highlighted multiple recent and pending acquisitions and partnerships as part of its growth strategy, including BioReference, Myriad prenatal health, and Millennium Health.
LabCorp reported third-quarter 2026 enterprise revenue of $3.8 billion, up 6.9% year over year, with adjusted operating income of $517 million, or 15% of revenue, versus $513 million and 14.4% last year. Adjusted EPS was $4.78, up 14.5%, and free cash flow was $412 million versus $281 million a year ago. Diagnostics revenue rose 6.5% to $2.9 billion with segment adjusted operating income of $492 million and margin of 16.7%; BLS revenue rose 8.5% to $867 million with adjusted operating income of $159 million and margin of 18.3%. For full-year 2026, enterprise revenue is now expected to grow 5.9% to 6.7%, adjusted EPS is guided to $18.30 to $18.70, and free cash flow remains guided to $1.24 billion to $1.36 billion. Management said the midpoint of enterprise revenue guidance increased by $65 million and adjusted EPS guidance increased by $0.18, while Launchpad remains on track for $125 million of full-year savings.
Adam Schechter framed the quarter as evidence that LabCorp is executing well across diagnostics and biopharma laboratory services, citing strong volume growth, margin expansion, and double-digit EPS growth. He emphasized that specialty testing is growing about 3x faster than the broader diagnostics market and described the company’s strategy as moving from investor day priorities into execution through specialty testing, technology, partnerships, and acquisitions. His tone was confident, especially on the company’s ability to absorb PAMA pressure over time through organic growth, BLS strength, Launchpad, and deal activity.
Julia Wang focused on the mechanics behind the quarter: enterprise revenue up 6.9%, adjusted operating margin up 60 basis points to 15%, adjusted EPS up 14.5% to $4.78, and free cash flow of $412 million. She said organic revenue growth was 5.5%, with acquisitions contributing 1.5% and FX a 0.1% drag, and noted diagnostics organic growth of 4.4% and BLS organic constant currency growth of 9.6%. She also said the company ended the quarter with $262 million in cash, $5.9 billion in total debt, and about $1.4 billion remaining under the share repurchase program, while reiterating capital allocation across acquisitions, dividends, and buybacks.
Analysts focused heavily on margin cadence, acquisitions, and PAMA. Management said margins should keep improving absent PAMA, but acknowledged 2027 would be tougher if the fee cut is implemented; they highlighted four offsets: underlying diagnostics, BLS, Launchpad, and business development. On the deals, management said the pipeline remains strong and argued the recently announced acquisitions are strategically aligned and expected to be accretive in year 1, with more detail to come in February 2027. They also addressed concerns about the BioReference economics by pointing to prior integration experience, cost structure visibility, and expected synergies from overlapping service centers and capacity rationalization.
The bullish case from the call is that LabCorp is showing sustained operating momentum: revenue growth, volume growth, and six straight quarters of enterprise margin progression. Management sounded confident that specialty testing, BLS demand, Launchpad savings, and tuck-in acquisitions can support growth into 2027 even with PAMA pressure, and it sees a strong pipeline of further deals. The company also pointed to growing capacity and broadening specialty offerings, including oncology, neurology, and women’s health.
The main risk discussed was PAMA, which management said could reduce 2027 reimbursement by about $125 million and make the implementation year meaningfully tougher. Analysts also pressed on whether acquisition margins are realistic, especially for BioReference, and management acknowledged that timing, integration, and service-center overlap will matter. There was also some concern around external factors like ACA-related volume headwinds and biotech funding, though management said those impacts are relatively limited or manageable.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.5%
- Shares Outstanding
- 81.20M
- Float Shares
- 80.81M
of shares held by institutions
1,073 13F filers
Buy/sell ratio 0.25. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for LH, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Sell | Oct 7, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 4, 26 | Filing → |
| April McClain DelaneyHouse · MD06 | Sell | Aug 7, 26 | Filing → |
| April McClain DelaneyHouse · MD06 | Sell | Aug 6, 26 | Filing → |
| April McClain DelaneyHouse · MD06 | Sell | Aug 25, 26 | Filing → |
| April McClain DelaneyHouse · MD06 | Sell | Aug 5, 26 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Tony WiedHouse · WI08 | Buy | Feb 19, 26 | Filing → |
| April McClain DelaneyHouse · MD06 | Buy | Feb 4, 26 | Filing → |
| April McClain DelaneyHouse · MD06 | Buy | Feb 11, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
| April McClain DelaneyHouse · MD06 | Buy | Jan 28, 26 | Filing → |
| April McClain DelaneyHouse · MD06 | Buy | Nov 17, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Oct 27, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 9.85M | ▲ 37.20K |
| Blackrock, Inc. | 6.54M | ▼ 38.76K |
| Vanguard Capital Management LLC | 5.31M | ▼ 52.32K |
| State Street Corp | 3.94M | ▲ 35.90K |
| Victory Capital Management Inc | 3.92M | ▼ 919.00K |
| Fmr LLC | 3.69M | ▲ 1.78M |
| Vanguard Portfolio Management LLC | 3.62M | ▼ 60.03K |
| Boston Partners | 2.95M | ▼ 103.16K |
| Geode Capital Management, LLC | 2.19M | ▼ 2.67K |
| Allspring Global Investments Holdings, LLC | 2.08M | ▼ 161.43K |
| Morgan Stanley | 1.60M | ▼ 13.48K |
| Invesco Ltd. | 1.54M | ▲ 300.36K |
Held by 1,771 ETFs
Biggest fund positions in LH by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Summy Amy B. | sell | 365 |
| Nov 10, 26 | Caveney Brian J | sell | 2,000 |
| Nov 3, 26 | Vaughn Bryan T | sell | 306 |
| Oct 30, 26 | Parham Richelle P | sell | 1,078 |
| Nov 1, 26 | Oyegunwa Akinbolade | other | 370 |
| Nov 2, 26 | Oyegunwa Akinbolade | other | 118 |
| Nov 1, 26 | Oyegunwa Akinbolade | other | 370 |
| Nov 1, 26 | Vaughn Bryan T | other | 500 |
| Nov 2, 26 | Vaughn Bryan T | other | 194 |
| Nov 1, 26 | Vaughn Bryan T | other | 500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LH coverage
Recent articles, reports, and earnings notes.
No research on LH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LH report →Worried investors are paying up for these stocks — some with up to 49% upside, analysts say
marketwatch.com · Nov 18
OTraces Selects Labcorp to Perform Biomarker Testing for Florida Department of Health–Funded Prostate Cancer Study
globenewswire.com · Nov 18
Labcorp to Expand Clinical Trial Operations in Brazil with Dedicated Kit Assembly and Future Laboratory Operations through Collaboration with Grupo Fleury
prnewswire.com · Nov 17
Why Labcorp Holdings (LH) is a Top Value Stock for the Long-Term
zacks.com · Nov 17
Labcorp (NYSE:LH) EVP Sells $744,080.00 in Stock
defenseworld.net · Nov 15
Fifth Third Bancorp Sells 6,956 Shares of Labcorp Holdings Inc. $LH
defenseworld.net · Nov 15
Labcorp Holdings Inc. $LH Stock Sold by Eurizon Capital SGR S.p.A.
defenseworld.net · Nov 15
Labcorp's Lab Growth Surges as $125 Million Reimbursement Risk Looms
marketbeat.com · Nov 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.